Celldex’s Rintega Phase III Study Recommended to Continue
Celldex Therapeutics, Inc. CLDX announced that an independent Data Safety and Monitoring Board (DSMB) completed its first pre-specified review of a phase III study (ACT IV) on Rintega (rindopepimut) and recommended the continuation of the study in patients with newly diagnosed glioblastoma. The randomized, double-blind, placebo controlled study on Rintega plus granulocyte-macrophage colony-stimulating factor (GM-CSF) added to standard-of-care treatment like Merck’s MRK Temodar (temozolomide) is being conducted in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. […]